James M. Apgar

Statistics

Publications

Citations

178

H-Index

Active since

2012

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Scynexis (United States)

James M. Apgar is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, medicinal chemistry, and enzyme inhibition.

ORCID

Publications per year

2012–2020

Publications

Ibrexafungerp: An orally active β-1,3-glucan synthesis inhibitor

James M. Apgar, Robert R. Wilkening, Dann L. Parker et al. · Bioorganic & Medicinal Chemistry Letters · 2020 · 50 citations

Medicine, Medicinal Chemistry, Pharmacology +4

Pharmacological AMPK activation induces transcriptional responses congruent to exercise in skeletal and cardiac muscle, adipose tissues and liver

Eric S. Muise, Hong-Ping Guan, Jinqi Liu et al. · PLoS ONE · 2019 · 43 citations · Full text

Life Sciences, Pharmacology, Physiology +16

Synthesis and biological evaluation of antifungal derivatives of enfumafungin as orally bioavailable inhibitors of β-1,3-glucan synthase

Brian Heasley, Gregory J. Pacofsky, Ahmed Mamai et al. · Bioorganic & Medicinal Chemistry Letters · 2012 · 34 citations

Medicine, Medicinal Chemistry, Pharmacology +16

Novel orally active inhibitors of β-1,3-glucan synthesis derived from enfumafungin

James M. Apgar, Robert R. Wilkening, Mark L. Greenlee et al. · Bioorganic & Medicinal Chemistry Letters · 2015 · 33 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +11

Structure–activity-relationship of amide and sulfonamide analogs of omarigliptin

Ping Chen, Dennis Feng, Xiaoxia Qian et al. · Bioorganic & Medicinal Chemistry Letters · 2015 · 18 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +9

1–5 of 5